The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

AI-powered algorithm can analyze video recordings of clinical sleep tests and more accurately diagnose REM sleep behavior disorder.

A Mount Sinai-led team of researchers has enhanced an artificial intelligence (AI)-powered algorithm to analyze video ...

The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to find out more information.

Adults with obstructive sleep apnea (OSA) are at increased risk for vertigo and vestibular dysfunction, relative to those without OSA.

Physical and emotional hyperactive symptoms associated with ADHD can have adverse effects on a person’s life. For instance, ...

Postmenopausal sleep issues contribute to a sharp decline in sleep quality among older women, beginning at approximately 51 ...

A recent study has found a surprising connection between sleep-related breathing problems and changes in the brain. Published ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Manufacturer Eli Lilly says the drug can be considered in patients with obesity who struggle with fatigue and daytime tiredness and who have an apnea-hypopnea index (AHI) of > 15 on a recent sleep ...